MATRIX-M1 ADJUVANT

Summary

Matrix-M1 Adjuvant (CHEMBL4650407) is a phase-3 clinical-stage unknown; indicated across 7 conditions including severe acute respiratory syndrome and malaria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 7 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650407
Name	MATRIX-M1 ADJUVANT
Type	Unknown
Max phase	3

Also known as: Matrix-m, Matrix-m1 adjuvant, MATRIX-M1 ADJUVANT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
malaria	3	MONDO:0005136	EFO:0001068
respiratory syncytial virus infectious disease	2	MONDO:0001577	EFO:1001413
influenza	2	MONDO:0005812	EFO:0007328
Plasmodium falciparum malaria	2	MONDO:0005920	EFO:0007444
Ebola hemorrhagic fever	1	MONDO:0005737	EFO:0007243

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1	5
PHASE2	4
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04704830	PHASE3	ACTIVE_NOT_RECRUITING	R21/Matrix-M in African Children Against Clinical Malaria
NCT03026348	PHASE2	COMPLETED	Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
NCT03658629	PHASE2	TERMINATED	Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
NCT03947190	PHASE2	TERMINATED	A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults
NCT04533399	PHASE2	COMPLETED	A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
NCT05683834	PHASE1/PHASE2	COMPLETED	Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
NCT02370589	PHASE1	COMPLETED	Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
NCT04271306	PHASE1	TERMINATED	Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
NCT04318002	PHASE1	COMPLETED	Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania
NCT05913973	PHASE1	COMPLETED	Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
NCT06507605	PHASE1	COMPLETED	Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).